和譽-B(02256.HK)治療晚期肝細胞癌藥獲美國批准開展臨床試驗
和譽-B(02256.HK)公布,其附屬和譽醫藥高選擇性小分子成纖維細胞生長因子受體4(FGFR4)抑制劑Irpagratinib (ABSK011)獲美國FDA批准可開展其單藥在晚期肝細胞癌(HCC)患者中的I期臨床試驗。
Irpagratinib是一款具有高選擇性的FGFR4小分子抑制劑,擬用於治療晚期實體瘤,尤其是存在FGFR4信號通路異常(如配體FGF19擴增/過表達,FGFR4突變/擴增/融合等)的晚期HCC、膽管癌及乳腺癌等。FGFR4信號通路是HCC分子靶向治療開發的一個很有前景的方向。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.